Clinical Trial Update: Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 [Phase 3]

View source ↗

Summary

Phase 3 trial daNIS-2 evaluating NIS793 in combination with standard-of-care chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• NIS793 (NIS-793)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Status: COMPLETED